JP Morgan Chase
ABEO icon

JP Morgan Chase’s Abeona Therapeutics ABEO Stock Holding History

JP Morgan Chase’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-699,000
Closed -$3.68M – 7485
2025
Q4 		$3.68M Buy
+699,000
New +$3.52M ﹤0.01% 3598

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's ABEO Position: Q2 2026 in Review

JP Morgan Chase reduced its Abeona Therapeutics (ABEO) stake by 81% in Q2 2026, selling an estimated $1.19M and leaving 50,505 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #5430.

JP Morgan Chase first reported a position in ABEO in Q2 2016 and has held it in 36 quarters since. The position peaked at $4.72M in Q2 2025. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • JP Morgan Chase held 50,505 shares of Abeona Therapeutics worth $286K as of Q2 2026.
  • JP Morgan Chase sold 215,992 Abeona Therapeutics shares in Q2 2026, an estimated $1.19M.
  • Abeona Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5430 holding.
  • JP Morgan Chase first reported a position in Abeona Therapeutics in Q2 2016 and has held it in 36 quarters since.
  • JP Morgan Chase's Abeona Therapeutics position peaked at $4.72M in Q2 2025.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.